Clinical trials: Invasive Candidiases
Mycoses
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A: which are refractory or resistant to…
- Trial name
- NCT00034658
- Testing
- Posaconazole
- Volunteers
- 336 people
- Sponsor
- Merck Sharp & Dohme LLC
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Candidemia, Invasive Candidiases
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C.
- Conditions
- Candidemia, Invasive Candidiases, Candida Infection
- Trial name
- APEX (NCT04148287)
- Testing
- APX001
- Where
- 2 sites in South Africa
- Volunteers
- 9 people
- Sponsor
- Basilea Pharmaceutica
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
- Trial name
- DIRECT (NCT01525095)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- T2 Biosystems
Fungemia, Neutropenia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system.
- Conditions
- Fungemia, Neutropenia, Candidiasis
- Trial name
- NCT00806351
- Testing
- Active Anidulafungin, Active Caspofungin
- Where
- 10 sites in Bosnia and Herzegovina, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Pfizer
Candidiasis
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.
- Trial name
- NCT00036179
- Testing
- FK463
- Where
- 23 sites in Austria, France and 6 more
- Volunteers
- 75 people
- Sponsor
- Astellas Pharma Inc
Invasive Fungal Infections
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
The aim of the study is to prospectively evaluate the safety and efficacy of micafungin when prescribed for prophylaxis or treatment of fungal infections in different real-world clinical conditions and centers, in pediatric…
- Trial name
- NCT03174457
- Testing
- Micafungin
- Where
- 16 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 120 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Invasive Candidiasis, Esophageal Candidiasis
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed
- Conditions
- Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
- Trial name
- NCT00607763
- Testing
- Micafungin (Mycamine)
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
Invasive Candidiasis, Invasive Aspergillosis
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
This is a multi-center, open-label, non-controlled, single-arm clinical trial to evaluate the safety, efficacy and population pharmacokinetics of Amphotericin B cholesteryl Sulfate Complex for Injection domestic formulations…
- Trial name
- NCT05707832
- Testing
- Amphotericin B cholesteryl Sulfate Complex for Injection
- Where
- China
- Volunteers
- 31 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Candidemia, Invasive Candidiasis
CRITIC - Treatment of Candidemia and Invasive Candidiasis
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
- Trial name
- CRITIC (NCT00670657)
- Testing
- AmBisome
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Candidiasis, Candidemia
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down.
- Trial name
- NCT00739934
- Testing
- voriconazole (Vfend)
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Candidemia, Invasive Candidiasis
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.
- Trial name
- NCT00548262
- Testing
- Anidulafungin, Voriconazole
- Where
- 13 sites in Brazil, Chile and 3 more
- Volunteers
- 54 people
- Sponsor
- Pfizer
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Mycoses
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A.
- Trial name
- NCT00034632
- Testing
- Posaconazole oral suspension
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
The purpose of this study is to determine whether voriconazole is safe and effective for the treatment of serious Candida infection and Candida infection of the esophagus in children and adolescents.
- Trial name
- NCT01092832
- Testing
- voriconazole
- Where
- 14 sites in China, Czechia and 6 more
- Volunteers
- 23 people
- Sponsor
- Pfizer
Candidemia
Serial Therapeutic and Antifungal Monitoring Protocol
The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture.
- Trial name
- STAMP (NCT02163889)
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- T2 Biosystems